Kang 2018 Exp Mol Med

From Bioblast
Jump to: navigation, search
Publications in the MiPMap
Kang YC, Son M, Kang S, Im S, Piao Y, Lim KS, Song MY, Park KS, Kim YH, Pak YK (2018) Cell-penetrating artificial mitochondria-targeting peptide-conjugated metallothionein 1A alleviates mitochondrial damage in Parkinson's disease models. Exp Mol Med 50:105.

» PMID: 30120245 Open Access

Kang YC, Son M, Kang S, Im S, Piao Y, Lim KS, Song MY, Park KS, Kim YH, Pak YK (2018) Exp Mol Med

Abstract: An excess of reactive oxygen species (ROS) relative to the antioxidant capacity causes oxidative stress, which plays a role in the development of Parkinson's disease (PD). Because mitochondria are both sites of ROS generation and targets of ROS damage, the delivery of antioxidants to mitochondria might prevent or alleviate PD. To transduce the antioxidant protein human metallothionein 1A (hMT1A) into mitochondria, we computationally designed a cell-penetrating artificial mitochondria-targeting peptide (CAMP). The recombinant CAMP-conjugated hMT1A fusion protein (CAMP-hMT1A) successfully localized to the mitochondria. Treating a cell culture model of PD with CAMP-hMT1A restored tyrosine hydroxylase expression and mitochondrial activity and reduced ROS production. Furthermore, injection of CAMP-hMT1A into the brain of a mouse model of PD rescued movement impairment and dopaminergic neuronal degeneration. CAMP-hMT1A delivery into mitochondria might be therapeutic against PD by alleviating mitochondrial damage, and we predict that CAMP could be used to deliver other cargo proteins to the mitochondria.


Bioblast editor: Plangger M O2k-Network Lab: KR Seoul Pak YK


Labels: MiParea: Respiration, mt-Medicine, Pharmacology;toxicology  Pathology: Parkinson's 

Organism: Human  Tissue;cell: Nervous system  Preparation: Isolated mitochondria 


Coupling state: OXPHOS  Pathway:HRR: Oxygraph-2k 

Labels, 2018-09